

Special Issue

Vaccine Candidate against SARS-CoV-2

Message from the Guest Editors

The quest for a vaccine against SARS-CoV-2 has mobilized a multitude of researchers worldwide that combined their expertise and effort for the rapid development of effective products. In this special issues, we want to highlight:

- the vaccine platforms already available before the COVID-19 pandemic, which have been quickly scaled-up to develop vaccines against SARS-CoV-2
- aspects related to the immunogenicity, safety and efficacy of licensed vaccines, including the durability of immune responses and the protection against variants
- new generations of vaccines/new vaccine candidates against COVID-19
- strategies to improve the efficacy of COVID-19 vaccination
- vaccination strategies for particular populations (e.g. children, the elderly, fragile subjects)
- immunological correlate of protection

Original research articles and short communications on pre-clinical and clinical studies are welcome, as well as reviews and commentaries.

Guest Editors

Prof. Dr. Antonella Caputo

Department of Chemical, Pharmacological and Agricultural Sciences,
University of Ferrara, 44121 Ferrara, Italy

Dr. Francesco Nicoli

Department of Chemical, Pharmaceutical and Agricultural Sciences,
University of Ferrara, 44123 Ferrara, Italy

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/88548

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).